NEW YORK — Consuming higher amount of red or processed meat may increase the risk of developing non-alcoholic fatty liver disease (NAFLD), researchers have warned.
“NAFLD is considered as the hepatic component of the metabolic syndrome, with insulin resistance and inflammation as key factors in its pathophysiology,” said lead author Shira Zelber-Sagi, Professor at the University of Haifa in Israel.
Researchers noted that high meat eaters were slightly younger, mainly male, had a higher body mass index (BMI), caloric intake and a worse metabolic profile.
In addition, individuals who consumed large quantities of meat cooked using unhealthy methods including, frying or grilling, had increased levels of high heterocyclic amines (HCAs) — pro-inflammatory compounds found in burned meat — and therefore developed insulin resistance.
People who are already diagnosed with NAFLD had similar consequences, along with an increased chance of cancer, Type 2 diabetes, and chronic heart diseases, researchers mentioned in the study, published in the Journal of Hepatology.
“Unhealthy Western lifestyle plays a major role in the development and progression of NAFLD, namely, lack of physical activity and high consumption of fructose and saturated fat,” Zelber-Sagi said.
“Our study looked at other common foods in the Western diet, namely red and processed meats, to determine whether they increase the risk for NAFLD,” she added.
In order to test the association of type of meat and cooking method with NAFLD and insulin resistance, the team included 357 participants, between 40 and 70 years of age.
NAFLD and insulin resistance were evaluated by ultrasonography and homeostasis model assessment (HOMA). Meat-type and cooking method were measured by food frequency and detailed meat consumption questionnaires.
Results showed that NAFLD was diagnosed in 38.7 per cent of participants and insulin resistance in 30.5 per cent.Follow @gorkhapost
Diabetes drug might ease heart failure risk
A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.
According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.
Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.
The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.
Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.
“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.
“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.
Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.
Their risk of kidney failure and death from kidney failure also fell, researchers noted.
Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.
With Inputs from HealthDayFollow @gorkhapost